Cystic Fibrosis Clinical Trials in Philadelphia, Pennsylvania

10 studies are recruiting for cystic fibrosis in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Genetics of Insulin and Incretins in Cystic Fibrosis

   Cystic fibrosis related diabetes (CFRD) is associated with worse CF-relevant outcomes. The mechanisms underlying CFRD development are not fully understood, but recent evidence suggests Type 2 Diabetes Mellitus (T2DM) mechanisms may be involved and may involve incretins (gut secreted hormones that a…

   Stage

   Not phased

   Ages

   2 and older

   Site

   The Children's Hopsital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   2 in total

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT01852448 on ClinicalTrials.gov

2. Remote Sputum Collection in Cystic Fibrosis

   Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collectin…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   4 in total

   Run by

   University of Pennsylvania

   See if you can join NCT06950892 on ClinicalTrials.gov

3. Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

   The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

   Stage

   Not phased

   Ages

   3 to 18

   Site

   Children's Hospital of Philadelphia & University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   33 in total

   Run by

   University of Washington, the Collaborative Health Studies Coordinating Center

   See if you can join NCT06654752 on ClinicalTrials.gov

4. Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

   This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).

   Stage

   Not phased

   Ages

   Up to 10

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   35 in total

   Run by

   Sonya Heltshe

   See if you can join NCT04509050 on ClinicalTrials.gov

5. Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

   The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs me…

   Stage

   Phase 4

   Ages

   6 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   60 in total

   Run by

   Chris Goss

   See if you can join NCT05548283 on ClinicalTrials.gov

6. GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

   Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative i…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   2 in total

   Run by

   University of Pennsylvania

   See if you can join NCT04731272 on ClinicalTrials.gov

7. Beta-cell Response to Incretin Hormones in Cystic Fibrosis

   In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. In…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT01851694 on ClinicalTrials.gov

8. Health Outcomes of Parents With Cystic Fibrosis-Aim 2

   The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators. The investigators will collect physical and mental health data to comprehensively evaluate the im…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   18 in total

   Run by

   University of Pittsburgh

   See if you can join NCT06296394 on ClinicalTrials.gov

9. A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

   The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to in…

   Stage

   Not phased

   Ages

   12 and older

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   68 in total

   Run by

   Nicole Hamblett

   See if you can join NCT06504589 on ClinicalTrials.gov

10. A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

    This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Hospital at University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    4 in total

    Run by

    Spirovant Sciences, Inc.

    See if you can join NCT06526923 on ClinicalTrials.gov